GlassScriptPhysician profile
Alexander T Page
NPI 1467743310
$1,029.40
in general payments reported to CMS, 2019-2025
21 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $47.39 · 2021: $31.86 · 2022: $116 · 2023: $59.80 · 2024: $135 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $311 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $310.60 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $154.49 | 2019-2025 | Vafseo, Auryxia |
| Bard Peripheral Vascular, INC. | $110.88 | 2019 | |
| Amgen INC. | $95.53 | 2019-2022 | |
| Vifor Pharma, INC. | $87.56 | 2019-2024 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $85.60 | 2019-2025 | Farxiga |
| Calliditas Therapeutics US INC. | $80.31 | 2022-2025 | Tarpeyo |
| Lilly USA, LLC | $61.13 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $50.73 | 2019 | |
| Mallinckrodt Enterprises LLC | $47.22 | 2019 | |
| Opko Pharmaceuticals, LLC | $38.69 | 2019-2022 | |
| Travere Therapeutics, INC. | $35.60 | 2024 | |
| Novo Nordisk INC | $24.25 | 2025 | Ozempic |
| Aurinia Pharma U.S., INC. | $20.00 | 2023 | Lupkynis |
| Lundbeck LLC | $19.97 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.79 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18.39 | 2021 | |
| Daiichi Sankyo INC. | $18.16 | 2019 | |
| La Jolla Pharmaceutical Company | $16.08 | 2024 | Giapreza |
| Mallinckrodt Hospital Products INC. | $15.78 | 2020 | |
| Horizon Therapeutics Plc | $15.77 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.